Sutro Biopharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
STRO Nasdaq 2830 www.sutrobio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sutro Biopharma, Inc.

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - Mar 15th, 2025 10:40 pm
Chipotle upgraded, Charter initiated: Wall Street’s top analyst calls - Mar 15th, 2025 1:40 pm
Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler - Mar 15th, 2025 1:20 pm
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ... - Mar 14th, 2025 7:00 pm
Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs - Mar 14th, 2025 12:18 pm
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’ - Mar 14th, 2025 11:57 am
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates - Mar 13th, 2025 11:30 pm
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights - Mar 13th, 2025 8:07 pm
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline - Mar 13th, 2025 8:05 pm
Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates - Mar 11th, 2025 9:40 pm
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference - Mar 3rd, 2025 9:05 pm
We're Not Very Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Rate - Jan 22nd, 2025 11:27 am
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 7th, 2025 9:05 pm
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale - Jan 7th, 2025 2:00 pm
Sutro Biopharma, Inc.'s (NASDAQ:STRO) latest 24% decline adds to one-year losses, institutional investors may consider drastic measures - Dec 19th, 2024 7:31 pm
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer - Dec 10th, 2024 1:00 pm
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know - Nov 18th, 2024 5:00 pm
Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Nov 15th, 2024 11:10 am
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates - Nov 13th, 2024 10:40 pm
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - Nov 13th, 2024 9:30 pm